英夫利昔单抗在溃疡性结肠炎中的疗作用评估

The Therapy Effect Evaluation of Infliximab in Ulcerative Colitis

目的评估英夫利昔单抗治疗的溃疡性结肠炎的临床疗效。方法将随机选取该院2012年8月—2013年8月收治的80例克确诊罗恩氏病患者随机分成对照组(40例)与治疗组(40例)。对照组予综合治疗,治疗组在综合治疗基础上给予静脉输注英夫利昔单抗5 mg/kg,分别于患者用药0、2、6周及以后每隔8周用药一次,疗程6个月。观察两组治疗前后临床疗效、生化指标。结果治疗后两组患者腹痛、腹泻、血便等临床症状不同程度缓解,内镜下病理改善,治疗组治疗总有效率为100%,高于对照组72.5%,各生化指标ESR、CRP、HB、ALB均有所改善,两组相比差异有统计学意义(P<0.05)。结论英夫利昔单抗可明显提高溃疡性结肠炎患者的临床疗效,改善生活质量。

Objective To evaluate the clinical effect of infliximab on patients of ulcerative colitis. Methods Select 80 cases of ulcerative colitis from our hospital in August 2012—August 2013, and randomly divided into control group and treatment group with40 cases per group. The control group received combined therapy,while the treatment group was treated with intravenous infliximab5 mg/kg besides the combined therapy, respectively in patients with medication for 0, 2, 6 weeks and every 8 weeks later in the same dose, a total of six months. Clinical curative effect and the restore of biochemical index were assessed before and after treatment. Results After treatment, clinical symptoms such as abdominal pain, diarrhea, bloody stool, ease to varying degrees, endoscopic pathological improved in two group,the total effective rate in the treatment group was 100%,higher than the control group72.5%,the biochemical indicators ESR,CRP,HB,ALB were improved, compared two groups, the difference had statistical significance(P<0.05). Conclusion Infliximab could significantly improve the clinical treatment effect of ulcerative colitis, improve the quality of life.